L14 - Antiviral drug discovery Flashcards

Intended Learning Outcomes • Being able to explain the fundamental principles of antiviral drug discovery and validation. • Knowing the main antiviral drug discovery pipelines. • Being able to describe key antiviral mechanisms. • Being familiar with major breakthroughs in antiviral treatment and their impact on public health. • Being aware of challenges in antiviral treatment, such as drug resistance, toxicity, and effective

1
Q

What are antiviral drugs?

A

Medications designed to inhibit viral replication by targeting specific stages of the viral life cycle.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference between broad-spectrum and specific antivirals?

A

Broad-spectrum antivirals target multiple viruses, while specific antivirals target a single virus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do entry inhibitors work?

A

They block viral attachment or fusion with the host cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What do polymerase inhibitors do?

A

They prevent viral genome replication by inhibiting RNA/DNA polymerases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do protease inhibitors work?

A

They prevent viral protein maturation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are immunomodulators?

A

Drugs that enhance the host immune response against the virus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Who proposed the “magic bullet” concept and what does it mean?

A

Paul Ehrlich in the early 1900s, suggesting drugs could selectively target pathogens without harming the host.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What was the first approved antiviral drug and for what disease?

A

Idoxuridine in 1962, for Herpes Simplex Keratitis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What breakthrough treatment achieved a 95% cure rate for Hepatitis C?

A

Direct-acting antivirals (DAAs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do neuraminidase inhibitors like oseltamivir (Tamiflu) treat influenza?

A

By blocking viral release from infected cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the three UK-approved antivirals for SARS-CoV-2?

A

Remdesivir, Molnupiravir, and Nirmatrelvir/Ritonavir.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the main challenges in antiviral drug development?

A

Drug resistance, delivery issues, toxicity, and treatment timing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How can AI contribute to antiviral drug discovery?

A

By accelerating compound screening and design.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why are monoclonal antibodies promising for viral infections?

A

They provide highly specific neutralization with immediate therapeutic effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

For how many viruses are antiviral therapies approved?

A

Less than 10 viruses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which virus has the most approved antiviral drugs?

A

HIV, with over 50 approved antiviral therapies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How many antivirals are approved for SARS-CoV-2?

A

Approximately 2.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

At what stages do antiviral drugs act?

A

Entry, genome replication, protein processing, viral release, and immune modulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What type of inhibitors block viral entry into host cells?

A

Entry inhibitors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which inhibitors prevent viruses from leaving infected cells?

A

Neuraminidase inhibitors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How do reverse transcriptase inhibitors work?

A

They block reverse transcription in retroviruses like HIV.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What led to increased antiviral development in the 1960s and 1970s?

A

The success of antibiotics and improved understanding of virus replication.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What was the initial method for antiviral drug discovery?

A

“Blind screening” – testing random chemicals for antiviral activity in cell cultures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the purpose of lead modification in drug development?

A

To reduce toxicity, increase solubility, and improve bioavailability.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How much does it cost to develop a new antiviral drug?

A

Around £1.3 billion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How long does it take to develop an antiviral drug?

A

10–12 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are the key steps in the drug discovery process?

A

Target identification, screening, lead optimization, preclinical testing, and clinical trials.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the difference between mechanism-based and cell-based screening?

A

Mechanism-based screening targets specific enzymes or receptors, while cell-based screening examines the effect on viral function in cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is high-throughput screening?

A

An automated method that tests thousands of compounds per day for antiviral activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Where do screened compounds come from?

A

Company-owned or national compound libraries.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What does structure-based drug design require?

A

The atomic structure of the target molecule and an understanding of its mechanism of action.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How does structure-based design improve drug development?

A

It allows the creation of ligands that bind to and inhibit specific viral targets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Give an example of structure-based design in antivirals.

A

The development of HIV-1 protease inhibitors like Saquinavir.

34
Q

What was the first FDA-approved antiretroviral drug for HIV?

A

AZT (zidovudine) in 1987.

35
Q

Does ART cure HIV?

A

No, but it turns HIV into a manageable chronic condition.

36
Q

What was the initial (old) treatment for HCV?

A

Interferon and ribavirin, which had low cure rates and severe side effects.

37
Q

Why are DAAs a major breakthrough?

A

They have fewer side effects and offer a realistic path toward HCV eradication.

38
Q

What is the primary target of DAAs?

A

HCV proteins involved in replication and assembly.

39
Q

Why are DAAs more effective than interferon-based treatments?

A

They directly inhibit viral components rather than relying on immune stimulation.

40
Q

What advantage do DAAs offer over previous treatments?

A

Higher cure rates, shorter treatment duration, and fewer side effects.

41
Q

What are subgenomic replicon RNAs?

A

Artificially transcribed viral RNA that allows for studying HCV replication in vitro.

42
Q

Why are Huh-7 cells used in HCV research?

A

They support the replication of HCV subgenomic replicons.

43
Q

What is the significance of stable HCV replicon cell clones?

A

They enable long-term studies of viral replication and drug testing.

44
Q

What complications can chronic HBV infection cause?

A

Cirrhosis, liver failure, and hepatocellular carcinoma.

45
Q

What was the first approved therapy for HBV?

A

Interferon-alpha, which has low success rates and severe side effects.

46
Q

What are nucleos(t)ide analogues (NAs)?

A

Drugs like tenofovir and entecavir that inhibit HBV reverse transcription but do not cure the infection.

47
Q

Why do HBV and HIV treatments overlap?

A

Both viruses use reverse transcription, making some drugs effective against both.

48
Q

Which HIV drug is also used for HBV treatment?

A

Tenofovir.

49
Q

What new HBV treatment strategies are under investigation?

A

RNA interference, CRISPR-based therapies, and immune modulators.

50
Q

What do cap-dependent endonuclease inhibitors do?

A

They prevent viral mRNA synthesis, stopping replication early.

51
Q

What type of virus is SARS-CoV-2?

A

A positive-sense, single-stranded RNA virus.

52
Q

What are the three main antivirals approved for SARS-CoV-2 in the UK?

A

Remdesivir, Molnupiravir, and Nirmatrelvir/Ritonavir.

53
Q

How does Remdesivir work?

A

It is a nucleoside analogue that competes with natural nucleotides to disrupt viral RNA replication.

54
Q

What is the only broad-spectrum antiviral in clinical use?

A

Ribavirin.

55
Q

How does Ribavirin work?

A

It mimics adenosine and guanine nucleosides, disrupting viral replication.

56
Q

Why are broad-spectrum antivirals challenging to develop?

A

They must balance effectiveness against multiple viruses while minimizing host toxicity.

57
Q

Why do viruses develop drug resistance quickly?

A

Many viruses, especially RNA viruses, have high mutation rates.

58
Q

How can resistance be reduced?

A

By using combination therapies that target multiple viral pathways.

59
Q

Why is monotherapy less effective?

A

It increases the likelihood of resistance development.

60
Q

What are monoclonal antibodies used for?

A

They provide targeted neutralization of viruses like Ebola and SARS-CoV-2.

61
Q

How is AI improving antiviral drug discovery?

A

Machine learning accelerates drug screening and optimization.

62
Q

What is personalized medicine in antiviral treatment?

A

Tailoring therapy based on a patient’s immune response and viral strain.

63
Q

What is the treatment for Ebola?

A

Monoclonal antibodies dramatically improve survival

64
Q

How do antiviral drugs differ from antibiotics?

A

Antiviral drugs inhibit viral replication at various stages but do not directly destroy viruses, unlike antibiotics, which target bacteria.

65
Q

Why is there a need for multiple antiviral drugs against the same virus?

A

Viruses, especially RNA viruses, have high mutation rates, leading to rapid resistance development, making multiple drugs targeting different stages of the viral life cycle essential.

66
Q

What are entry inhibitors, and how do they work?

A

Entry inhibitors prevent viruses from entering host cells, blocking infection at the earliest stage.

67
Q

What is the function of genome replication inhibitors in antiviral therapy?

A

They target viral polymerases or reverse transcriptases, preventing the virus from replicating its genome.

68
Q

How do integrase inhibitors combat viral infections?

A

They block the integration of viral DNA into the host genome, preventing the virus from establishing a persistent infection.

69
Q

What role do immune modulators play in antiviral treatment?

A

They enhance the host’s immune response to help fight viral infections more effectively.

70
Q

What are the key stages of antiviral drug discovery?

A

Target identification, in vitro testing, in vivo testing, and clinical trials.

71
Q

Why is high-throughput screening important in antiviral drug discovery?

A

It allows rapid testing of large compound libraries to identify potential antiviral candidates efficiently.

72
Q

What is mechanism-based screening in antiviral drug development?

A

It focuses on assessing specific effects on viral targets, such as protease activity, to identify effective drug candidates.

73
Q

How did combination antiretroviral therapy (cART) change HIV treatment?

A

It transformed HIV into a manageable condition by using multiple drugs to suppress viral replication and reduce resistance.

74
Q

What was the major breakthrough in hepatitis C treatment?

A

The shift from interferon-based therapies to direct-acting antivirals (DAAs), which achieved over 95% cure rates.

75
Q

What is the current main treatment strategy for hepatitis B?

A

Nucleoside analogues, though research is ongoing to develop curative therapies.

76
Q

When and why must influenza antivirals be given early?

A

They are most effective within 48 hours of symptom onset, as they prevent viral particle release early in the infection.

77
Q

What antiviral drug strategies were developed for SARS-CoV-2?

A

Protease and polymerase inhibitors were rapidly developed and approved during the COVID-19 pandemic.

78
Q

Why is drug resistance a major challenge in antiviral therapy?

A

Resistant variants can emerge quickly, especially in chronic infections, reducing drug effectiveness.

79
Q

How might AI-driven drug design impact antiviral discovery?

A

AI could accelerate the identification of new antiviral compounds and improve drug optimisation.

80
Q

What is the role of personalised medicine in future antiviral treatments?

A

It aims to tailor antiviral therapies based on individual genetic profiles to enhance effectiveness.

81
Q

Why is continued research essential in antiviral drug discovery?

A

New viral threats constantly emerge, requiring novel and effective antiviral strategies.